Announcements Trials
Browse Landscape

Status

Completed 4Recruiting 2Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 8Observational 4

Sponsor

Cancer Type

NET 3Endocrine 3Gastrointestinal 1

Conditions

Neuroendocrine Tumors 2Somatostatin Receptor-positive Neuroendocrine Tumor 1Somatostatin Receptor-positive GEP-NET 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Surveys and Questionnaires 286Blood Specimen Collection 145Gene Expression Profiling 96Interviews as Topic 83Immunohistochemistry 78Polymerase Chain Reaction 64Surgical Procedures, Operative 62Magnetic Resonance Spectroscopy 59Microarray Analysis 55Flow Cytometry 53Radiotherapy 49Amplified Fragment Length Polymorphism Analysis 48Drug Therapy 46Observation 45Biopsy 42Bevacizumab 40Reverse Transcriptase Polymerase Chain Reaction 39Data Collection 35Sorafenib 29Psychiatric Rehabilitation 29Nivolumab 28palbociclib 26In Situ Hybridization, Fluorescence 26Rituximab 25Hepatectomy 25Therapeutics 24Neoadjuvant Therapy 24Docetaxel 24Colonoscopy 24Sunitinib 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Observational × lutetium Lu 177 dotatate × Clear all
NCT04727723 2026-05-04

REAL-LU

Novartis

Completed
164 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT05844332 2025-12-22

LUTATHERA Injection General Use Result Survey

Novartis

Completed
347 enrolled
EndocrineNET

Somatostatin Receptor-positive Neuroendocrine Tumor

NCT04946305 2024-08-09

A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea

Novartis

Completed
89 enrolled

Somatostatin Receptor-positive GEP-NET

NCT05816720 2023-04-18

Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)

Novartis

Completed
31 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡